NCT02336607
The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
See it on ClinicalTrials.gov ↗481 people
44.7%
55.3%
215 womenmiddle line = equal numbers266 men
- Phase
- NA
- Paid for by
- AstraZeneca
- Finished
- 2006-08
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 35 Years – 79 Years
- Average age
- mean 54.9 Years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnancy or lactation.”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnancy or lactation.”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Other clinical significant arrhythmia”
- No diabetes
Women with diabetes were turned away.
“Type 1 diabetes mellitus”
Study titles and rules are shown in their original English.